Affimed N.V. (AFMD)

NASDAQ: AFMD · Real-Time Price · USD

1.09

0.10 (9.55%)

At close: May 01, 2025, 3:54 PM

1.01

-7.34%

After-hours: May 01, 2025, 05:01 PM EDT

9.55% (1D)

Bid	0.96
Market Cap	16.6M
Revenue (ttm)	877K
Net Income (ttm)	-69.97M
EPS (ttm)	-5.19
PE Ratio (ttm)	-0.21
Forward PE	-0.42
Analyst	Buy

Ask	1.1
Volume	164,690
Avg. Volume (20D)	98,536
Open	1.01
Previous Close	0.99
Day's Range	0.99 - 1.13
52-Week Range	0.52 - 8.95
Beta	2.28

About AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 12, 2014

Employees 76

Stock Exchange NASDAQ

Ticker Symbol AFMD

Website https://www.affimed.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for AFMD stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 1046.79% from the latest price.

Stock Forecasts

Next Earnings Release

Affimed N.V. is scheduled to release its earnings on May 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

-29.11%

Affimed shares are trading lower. The company repo... Unlock content with Pro Subscription

11 months ago

+68.51%

Affimed shares are trading higher after the company announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.

News

1 day ago · https://www.marketscreener.com

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improv...